Seong H Yoo1, Kyoungbun Lee, Ji Y Chae, Kyung C Moon. 1. Department of Forensic Medicine and Institute of Forensic Medicine, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea.
Abstract
AIMS: CD151 is known to be implicated in cancer progression and metastasis. The aim was to evaluate the expression of CD151 in clear cell renal cell carcinoma (CCRCC) and to assess its prognostic significance. METHODS AND RESULTS: The expression of CD151 was evaluated in 489 cases of CCRCC by immunohistochemistry. Immunoreactivity was classified into four categories (minimal, 0-10% positive cells; focal, 10-50% positive cells; diffuse moderate, >50% positive cells with moderate staining intensity; diffuse strong, >50% positive cells with strong staining). To determine the statistical significance of CD151 expression in CCRCC, all cases were divided into two groups based on their CD151 expression level: a CD151-low group (n=257; minimal and focal) and a CD151-high group (n=232; diffuse). Expression of CD151 was correlated positively with pT, pN, pM categories, pathological tumour-node-metastasis (pTNM) stage, nuclear grade, tumour size and patient's age. The CD151-high group had significantly shorter cancer-specific survival (P<0.001) and progression-free survival (P<0.001) times. Furthermore, multivariate analysis showed that CD151 expression was an independent predictor for tumour progression in patients with CCRCC (P=0.040). CONCLUSIONS: High CD151 expression is associated with advanced stage and high nuclear grade in CCRCC. CD151 is a prognostic marker for tumour progression in CCRCC patients.
AIMS: CD151 is known to be implicated in cancer progression and metastasis. The aim was to evaluate the expression of CD151 in clear cell renal cell carcinoma (CCRCC) and to assess its prognostic significance. METHODS AND RESULTS: The expression of CD151 was evaluated in 489 cases of CCRCC by immunohistochemistry. Immunoreactivity was classified into four categories (minimal, 0-10% positive cells; focal, 10-50% positive cells; diffuse moderate, >50% positive cells with moderate staining intensity; diffuse strong, >50% positive cells with strong staining). To determine the statistical significance of CD151 expression in CCRCC, all cases were divided into two groups based on their CD151 expression level: a CD151-low group (n=257; minimal and focal) and a CD151-high group (n=232; diffuse). Expression of CD151 was correlated positively with pT, pN, pM categories, pathological tumour-node-metastasis (pTNM) stage, nuclear grade, tumour size and patient's age. The CD151-high group had significantly shorter cancer-specific survival (P<0.001) and progression-free survival (P<0.001) times. Furthermore, multivariate analysis showed that CD151 expression was an independent predictor for tumour progression in patients with CCRCC (P=0.040). CONCLUSIONS: High CD151 expression is associated with advanced stage and high nuclear grade in CCRCC. CD151 is a prognostic marker for tumour progression in CCRCC patients.
Authors: Marina O Golovastova; Dmitry O Korolev; Larisa V Tsoy; Vladimir A Varshavsky; Wan-Hai Xu; Andrey Z Vinarov; Evgeni Yu Zernii; Pavel P Philippov; Andrey A Zamyatnin Journal: Curr Urol Rep Date: 2017-01 Impact factor: 3.092
Authors: M J Kwon; S Park; J Y Choi; E Oh; Y J Kim; Y-H Park; E Y Cho; M J Kwon; S J Nam; Y-H Im; Y K Shin; Y-L Choi Journal: Br J Cancer Date: 2012-01-31 Impact factor: 7.640
Authors: Marie C Hogan; Kenneth L Johnson; Roman M Zenka; M Cristine Charlesworth; Benjamin J Madden; Doug W Mahoney; Ann L Oberg; Bing Q Huang; Alexey A Leontovich; Lisa L Nesbitt; Jason L Bakeberg; Daniel J McCormick; H Robert Bergen; Christopher J Ward Journal: Kidney Int Date: 2013-11-06 Impact factor: 10.612
Authors: Séverine Roselli; Richard G S Kahl; Ben T Copeland; Matthew J Naylor; Judith Weidenhofer; William J Muller; Leonie K Ashman Journal: BMC Cancer Date: 2014-07-11 Impact factor: 4.430